IceCure Medical Ltd. (ICCM) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.03

From 52W high−93.89%

Volume75159.00

Market cap$6.72M

P/E (TTM)—

P/S (TTM)1.7x

Div yield—

Key dataSep 18, 2026

Open

$2.03

From 52W high

−93.89%

Volume

75159.00

Market cap

$6.72M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.3x

P/E (TTM)

—

RSI (14)

29.3

MomentumView details →

1D Return

−1.51%

YTD Return

−89.15%

SummaryUpdated Jun 1, 2026

IceCure Medical Ltd (NASDAQ:ICCM) is an Israeli medical device company founded in 2006 and headquartered in Caesarea, Israel. The company went public on NASDAQ in August 2021. IceCure specializes in developing and commercializing cryoablation technology, which uses extreme cold to destroy diseased tissue, particularly for cancer treatment. The company's flagship product, the ProSense system, is designed to treat breast tumors through minimally invasive cryoablation procedures. IceCure is currently awaiting FDA approval for its ProSense system in the United States while maintaining commercial operations in international markets.

Ask drillr about IceCure Medical Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.3x

EV/Sales

−1.3x

P/S (TTM)

1.7x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

36.10%

Net Margin

−427.67%

EBITDA Margin

−416.49%

ROE (TTM)

−141.90%

ROA (TTM)

−95.33%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+41.62%

EPS YoY

−79.42%

FCF YoY

−14.91%

Revenue CAGR 3Y

+3.08%

EPS CAGR 3Y

+21.11%

EBITDA YoY

−5.76%

MomentumView details →

1D Return

−1.51%

YTD Return

−89.15%

1Y Return

−93.70%

RSI (14)

29.3

vs 50D SMA

−28.03%

vs 200D SMA

−81.52%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

2.87x

Quick Ratio

2.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.54

EPS Surprise

−1.32%

Beats (12Q)

3/12

Next Q EPS Est

−$1.16

Avg Surprise (4Q)

−35.33%

Rev Surprise

−35.51%

Financials snapshotView financials →

Revenue (TTM)

3.95M

Net Income (TTM)

−16.88M

Op. CF (TTM)

−16.32M

Next earningsNov 18, 2026 →

Latest newsMore news →

IceCure Medical received regulatory approval to market its ProSense cryoablation system in China.10d ago

IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.27d ago

Similar companies

enVVeno Medical CorporationNVNO 20/20 Biolabs, Inc. Common StockAIDX Autonomix Medical, Inc. Common StockAMIX Bone Biologics CorporationBBLGW Aethlon Medical, Inc.AEMD Pheton Holdings Ltd Class A Ordinary SharesPTHL Find similar companies →

Latest newsMore news →

IceCure Medical received regulatory approval to market its ProSense cryoablation system in China.10d ago IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.27d ago IceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute approved its post-marketing ChoICE Study for ProSense cryoablation in low-risk breast cancer treatment.31d ago